Summary & Overview
HCPCS Level II J0402: Aripiprazole Injection, 1 mg
HCPCS Level II code J0402 designates a 1 mg syringe unit of injectable aripiprazole (brand: Abilify Asimtufii). This code matters nationally because aripiprazole injections are used in psychiatric care for conditions such as schizophrenia and bipolar disorder, and standardized HCPCS coding supports consistent billing for the drug component of injectable therapy across outpatient and ambulatory settings. Accurate use of J0402 affects drug cost reporting, payer coverage determinations, and facility reimbursement for medication supply.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for injectable aripiprazole, payer coverage framing, and the typical sites of service where the code is applied. The publication also summarizes benchmarks and policy-relevant information that impact billing and coverage for injectable antipsychotic therapies, and highlights where readers can expect variation in coverage or prior authorization practices.
This national summary is intended to help billing managers, compliance staff, and policy analysts understand what J0402 represents, where it is used, and which payers commonly influence payment and utilization patterns. Data not available in the input.
Billing Code Overview
HCPCS Level II code J0402 represents an injection of aripiprazole (Abilify Asimtufii), 1 mg. This code is used to report the medication product and dose administered for injectable aripiprazole.
Service Type: Medication administration / injectable antipsychotic
Typical Site of Service: Outpatient clinic, office, behavioral health center, or other ambulatory care settings where injectable psychiatric medications are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with schizophrenia, schizoaffective disorder, or bipolar I disorder who presents for a scheduled long-acting antipsychotic injection conversion or maintenance dose. The patient arrives at an outpatient behavioral health clinic, community mental health center, or ambulatory infusion suite for administration of intramuscular J0402 (aripiprazole, 1 mg unit). Clinical workflow includes registration and verification of insurance and consent, nursing medication reconciliation and assessment for current symptoms and adverse effects, verification of the prescribed dose and product (calculated in mg and correlated to vial or syringe volume), preparation of the medication under aseptic technique, administration via deep intramuscular injection (deltoid or gluteal) by a licensed nurse or prescriber, and 15–30 minute post-injection monitoring for immediate adverse reactions. Documentation includes the exact units administered (number of mg), lot number, expiration date, injection site, patient tolerance, and follow-up plan. Typical sites of service are outpatient clinic, behavioral health center, and ambulatory care settings; inpatient administration may occur when indicated for acute stabilization. Common patient scenarios include transitioning from oral antipsychotic therapy to long-acting injectable aripiprazole, adherence-challenged patients needing supervised administration, or monthly maintenance dosing for stabilized psychiatric disorders.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |